利妥昔单抗和慢性淋巴细胞白血病相关复发性微小巴贝斯虫感染的阿托伐醌和阿奇霉素耐药的临床和分子证据。
Clinical and Molecular Evidence of Atovaquone and Azithromycin Resistance in Relapsed Babesia microti Infection Associated With Rituximab and Chronic Lymphocytic Leukemia.
机构信息
Department of Medicine, Division of Infectious Diseases.
Department of Pathology and Laboratory Medicine.
出版信息
Clin Infect Dis. 2017 Oct 1;65(7):1222-1225. doi: 10.1093/cid/cix477.
Abstract
Babesiosis treatment failures with standard therapy have been reported, but the molecular mechanisms are not well understood. We describe the emergence of atovaquone and azithromycin resistance associated with mutations in the binding regions of the target proteins of both drugs during treatment of an immunosuppressed patient with relapsing babesiosis.
摘要
已经报道了使用标准疗法治疗巴贝斯虫病失败的案例，但分子机制尚不清楚。我们描述了在一名复发性巴贝斯虫病免疫抑制患者的治疗过程中，阿托伐醌和阿奇霉素耐药性的出现与两种药物靶蛋白结合区域突变有关。
相似文献
1
Clinical and Molecular Evidence of Atovaquone and Azithromycin Resistance in Relapsed Babesia microti Infection Associated With Rituximab and Chronic Lymphocytic Leukemia.
Clin Infect Dis. 2017 Oct 1;65(7):1222-1225. doi: 10.1093/cid/cix477.
2
Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection.
Clin Infect Dis. 2010 Feb 1;50(3):381-6. doi: 10.1086/649859.
3
Combination of Clofazimine and Atovaquone as a Potent Therapeutic Regimen for the Radical Cure of Babesia microti Infection in Immunocompromised Hosts.
J Infect Dis. 2022 Jan 18;225(2):238-242. doi: 10.1093/infdis/jiab537.
4
Atovaquone and azithromycin treatment for babesiosis in an infant.
Pediatr Infect Dis J. 2007 Feb;26(2):181-3. doi: 10.1097/01.inf.0000250622.11505.8f.
5
Efficacy, safety and tolerance of imidocarb dipropionate versus atovaquone or buparvaquone plus azithromycin used to treat sick dogs naturally infected with the Babesia microti-like piroplasm.
Parasit Vectors. 2017 Mar 13;10(1):145. doi: 10.1186/s13071-017-2049-0.
6
Misdiagnosis of Babesiosis as Malaria, Equatorial Guinea, 2014.
Emerg Infect Dis. 2018 Aug;24(8):1588-1589. doi: 10.3201/eid2408.180180.
7
Babesiosis in Long Island: review of 62 cases focusing on treatment with azithromycin and atovaquone.
Ann Clin Microbiol Antimicrob. 2017 Apr 11;16(1):26. doi: 10.1186/s12941-017-0198-9.
8
Atovaquone in the treatment of Babesia microti infections in hamsters.
Am J Trop Med Hyg. 1996 Aug;55(2):219-22. doi: 10.4269/ajtmh.1996.55.219.
9
Congenital babesiosis in a four-week-old female infant.
Pediatr Infect Dis J. 2010 Feb;29(2):188. doi: 10.1097/INF.0b013e3181c3c971.
10
Atovaquone and azithromycin for the treatment of babesiosis.
N Engl J Med. 2000 Nov 16;343(20):1454-8. doi: 10.1056/NEJM200011163432004.
引用本文的文献
1
Efficacy and mechanism of action of cipargamin as an antibabesial drug candidate.
Elife. 2025 Jun 19;13:RP101128. doi: 10.7554/eLife.101128.
2
Design and screening of novel molecular compounds targeting lactate dehydrogenase of Babesia microti.
Parasit Vectors. 2025 Feb 23;18(1):69. doi: 10.1186/s13071-024-06623-9.
3
Persistent human babesiosis with low-grade parasitemia, challenges for clinical diagnosis and management.
Heliyon. 2024 Nov 3;10(22):e39960. doi: 10.1016/j.heliyon.2024.e39960. eCollection 2024 Nov 30.
4
Evaluating Antimalarial Proteasome Inhibitors for Efficacy in Blood Stage Cultures.
ACS Omega. 2024 Oct 28;9(45):44989-44999. doi: 10.1021/acsomega.4c04564. eCollection 2024 Nov 12.
5
efficacy of next-generation dihydrotriazines and biguanides against babesiosis and malaria parasites.
Antimicrob Agents Chemother. 2024 Sep 4;68(9):e0042324. doi: 10.1128/aac.00423-24. Epub 2024 Aug 13.
6
Tafenoquine for Relapsing Babesiosis: A Case Series.
Clin Infect Dis. 2024 Jul 19;79(1):130-137. doi: 10.1093/cid/ciae238.
7
Tafenoquine-Atovaquone Combination Achieves Radical Cure and Confers Sterile Immunity in Experimental Models of Human Babesiosis.
J Infect Dis. 2024 Jan 12;229(1):161-172. doi: 10.1093/infdis/jiad315.
8
Babesia BdFE1 esterase is required for the anti-parasitic activity of the ACE inhibitor fosinopril.
J Biol Chem. 2023 Nov;299(11):105313. doi: 10.1016/j.jbc.2023.105313. Epub 2023 Oct 4.
9
Plasma Blood Levels of Tafenoquine following a Single Oral Dosage in BALBc Mice with Acute Infection That Resulted in Rapid Clearance of Microscopically Detectable Parasitemia.
Pathogens. 2023 Aug 31;12(9):1113. doi: 10.3390/pathogens12091113.
10
Comparison of the Efficacy of Longer versus Shorter Pulsed High Dose Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post Treatment Lyme Disease Syndrome with Bartonellosis and Associated Coinfections.
Microorganisms. 2023 Sep 12;11(9):2301. doi: 10.3390/microorganisms11092301.
本文引用的文献
1
A global map of genetic diversity in Babesia microti reveals strong population structure and identifies variants associated with clinical relapse.
Nat Microbiol. 2016 Jun 13;1(7):16079. doi: 10.1038/nmicrobiol.2016.79.
2
Diagnosis, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: A Review.
JAMA. 2016 Apr 26;315(16):1767-77. doi: 10.1001/jama.2016.2884.
3
Persistence of babesiosis for >2 years in a patient on rituximab for rheumatoid arthritis.
Diagn Microbiol Infect Dis. 2016 Jun;85(2):231-2. doi: 10.1016/j.diagmicrobio.2016.02.016. Epub 2016 Feb 21.
4
Sequence and annotation of the apicoplast genome of the human pathogen Babesia microti.
PLoS One. 2014 Oct 3;9(10):e107939. doi: 10.1371/journal.pone.0107939. eCollection 2014.
5
Structural analysis of atovaquone-inhibited cytochrome bc1 complex reveals the molecular basis of antimalarial drug action.
Nat Commun. 2014 Jun 4;5:4029. doi: 10.1038/ncomms5029.
6
Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection.
Clin Infect Dis. 2010 Feb 1;50(3):381-6. doi: 10.1086/649859.
7
Persistent and relapsing babesiosis in immunocompromised patients.
Clin Infect Dis. 2008 Feb 1;46(3):370-6. doi: 10.1086/525852.
8
In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin.
J Biol Chem. 2007 Jan 26;282(4):2494-504. doi: 10.1074/jbc.M608615200. Epub 2006 Nov 15.
9
The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America.
Clin Infect Dis. 2006 Nov 1;43(9):1089-134. doi: 10.1086/508667. Epub 2006 Oct 2.
10
Ribosomal mutations in Streptococcus pneumoniae clinical isolates.
Antimicrob Agents Chemother. 2002 Mar;46(3):654-8. doi: 10.1128/AAC.46.3.654-658.2002.
Zotero 插件